{"entity":{"id":"cd27","kind":"target","name":"CD27","aka":["TNFRSF7","CD27 molecule","Tp55","S152"],"tldr":"CD27 is an accelerator on most T cells that is pressed by CD70. Agonist antibodies against it reached phase 2 in lymphoma; its partner CD70 is a separate target for antibodies and CAR-T cells.","summary":"CD27 (chromosome 12p13.31) is a costimulatory immune-checkpoint receptor on T cells, NK cells and B cells that is activated by its ligand CD70 on B cells; CD70-CD27 signalling mediates antigen-specific T-cell activation and expansion (UniProt P26842). It is found in most T lymphocytes. Varlilumab (CDX-1127), a CD27 agonist antibody, reached phase 2 with nivolumab in relapsed aggressive B-cell lymphoma (NCT03038672); several combination studies were terminated for portfolio re-prioritisation (NCT02386111).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:11922","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11922"},{"label":"UniProt P26842","url":"https://www.uniprot.org/uniprotkb/P26842/entry"},{"label":"NCBI Gene 939","url":"https://www.ncbi.nlm.nih.gov/gene/939"},{"label":"ClinicalTrials.gov NCT03038672","url":"https://clinicaltrials.gov/study/NCT03038672"}],"tags":["checkpoint-map"],"related":["cd70","nivolumab","cd137"],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"CD27","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:11922","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11922","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt P26842","url":"https://www.uniprot.org/uniprotkb/P26842/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:11922","ensembl":"ENSG00000139193","uniprot":"P26842","entrez":"939","biology":"A TNF-receptor-superfamily costimulator; the CD70 side has its own target page.","whereFound":["Most T lymphocytes; NK and B cells (UniProt P26842)","B-cell lymphoma trials of varlilumab (NCT03038672)"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/cd27/","neighbours":{"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}